" What lies behind us, what lies before us, are small matters compared to what lies within us" R.W. Emmerson
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SGWV... news out... nice play today...IMHO
Strategic Growth Ventures, Inc. Announces Agreement in Principal to Purchase Water Recovery Operations
May 18, 2006 2:12:00 PM
Copyright Business Wire 2006
TAMPA, Fla.--(BUSINESS WIRE)--May 18, 2006--
Today Strategic Growth Ventures (Pink Sheets:SGWV) announced today it has reached an agreement in principal to purchase World First Water Recovery Corp. for preferred stock. SGWV will issue Preferred Stock for the purchase.
World First Water Recovery Corp. provides services and equipment for water treatment and purification. The initial contract in this agreement is being negotiated. It is expected to provide $53 million in revenue with approximately $10 million in net income. The duration of the contract as currently negotiated provides for three years of operations with an additional one year extension possible. The operation will treat 25,000 barrels of water per day from oil production. It will take five months to install the equipment. The first revenue should be realized in November 2006. The final contract will be signed before the end of May 2006.
"We are changing the focus of the operations to provide a substantial business opportunity for the company," stated Michael Elliott, President of Strategic Growth Ventures, Inc.
About Strategic Growth Ventures:
Strategic Growth Ventures, Inc. invests in emerging growth companies with market-ready products, strong management teams, and strategies for developing high growth companies in well defined markets.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Source: Strategic Growth Ventures, Inc.
HBSc... .20x.22 UP.03 nice bid support.... imho... VERY NICE PLAY...
I am liking HOGC.nice play today ..imho... I loaded in a bit
HBSc... .20x.21 imho a nice play
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTCBB: HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Source: Market Wire (May 16, 2006 - 11:49 AM EDT)
News by QuoteMedia
HBSc..lok at L2.... easy uptick today.....imho
HBSC... 20x.21 the news is kicking in... up .03 first half hour... strong buy ..IMHO
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
HBSc... up.03 on 52K vol.... .20x.21 NEWS yesterday is doing somethinhg.... imho
HBSC.... .20x.21 buying coming in... up.03 on 52K vol... a totalt up tick today...imho
I would agree on the eyes r on oil.. made a few $$$$$ over the past few weeks...myself I have a really nice oil play that I am looking at now... will post info when I make my decision... in the mean time HBSC.... at the level that is a TOTAL BUY... IMHO..
HBSc has nothing but good news for investors.... thast also in imho...nite all
we are geting slammed today.. I dont get it...lol.. it is a STRONG BUY AT THIS LEVEL... IMHO
HBSc buying and selling... .181x.195........ imho a strong buy at the low... I jsut got off the phone with ther CEO... holly S... I am goiong in stronger... looks like someone got cold feet... good.... I am adv down
ALERT HBSC...195x.205 imho strong buy at this level...IMHO...
what a buy.. .195x.205 HBSC... imho... 152.531 vol
HBSC... .205x.219 niceeeeeeeeeee play at this level....imho
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
HBSc... low for the year.. nice bounce about to happen imho..
NEWS OUT YESTERDAY....
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
HBSC.. news out yeasterday... UNREAL 4th patent... reason to believe MORE news is headed our way... imho...
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
HBSc.. reason to believe more news is HEADED out... yesterdays {R about 4th patent... unreal... new low.. holding its own at .205x.21 darnnnnnnnn imho it is a buy
HBSC... pick at .35-.40 very quiet... nice play at this ;evel... imho.. this stock is about to take off.....imho....eom
HBSC... very quiet.... .205x.219.... total nice play at this level... every time I have reason to believe we will have news .. I am on target..
Yes.. I am hearing alot about theis company.... I heard that the PR was sent out to all kinds of press.... not jsut the market wire... I have a feeling we will be seeing ALOT of press on HBSC..... I sure hope so..
some older press on HBSC.. nice read...
http://www.bizjournals.com/sanjose/stories/2005/10/31/daily26.html
some old press on HBSC...
http://www.bizjournals.com/sanjose/stories/2005/10/31/daily26.html
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
HBSC...21x.22 BREAK OUT of THE .22... hello .27-.30 imo
gn traders.. have a good night
HBSc...20x.215 6 MMon the bid at .20
http://www.otcbb.com/asp/headlines.asp?sSymbol=hbsc
HBSc....20x.215 6 MMon the bid at .20
http://www.otcbb.com/asp/headlines.asp?sSymbol=hbsc
HBSc....20x.215 6 MM on the bid at .20
http://www.otcbb.com/asp/headlines.asp?sSymbol=hbsc
HBSc...... .20x.215 6 MM on the bid at .20
http://www.otcbb.com/asp/headlines.asp?sSymbol=hbsc
HBSC.... 20x.215... 6MM on the bid at .20
news out today...
.20x.215 6 MM on the bid at .20 HBSC...
NEWS OUT today....
Press Release Source: Human BioSystems
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
Tuesday May 16, 11:49 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 16, 2006 -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (OTC BB:HBSC.OB - News) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
3rd vol alert in 7 days.. HBSC
http://cobrand.knobias.com/otcbb/story.htm?eid=3.1.0907a6a2aaa930a945a8aefb516d93f0b4cf85683315f5706...
3rd vol alert in 7 days.. HBSC
http://cobrand.knobias.com/otcbb/story.htm?eid=3.1.0907a6a2aaa930a945a8aefb516d93f0b4cf85683315f5706...
HBSc... 215x.229
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
HBSC
0.205 -0.025 News
Enter Symbol:
Enter Keyword:
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
jca@concetcg.com
SOURCE: Human BioSystems
mailto:hmasuda@humanbiosystems.com
mailto:rich@yesinternational.com
mailto:jca@concetcg.com
Copyright 2006 Market Wire, All rights reserved.
HBSC....215x.229... vol 318,115 come on .27 next level.. go HBSC
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
HBSC
0.205 -0.025 News
Enter Symbol:
Enter Keyword:
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
jca@concetcg.com
SOURCE: Human BioSystems
mailto:hmasuda@humanbiosystems.com
mailto:rich@yesinternational.com
mailto:jca@concetcg.com
Copyright 2006 Market Wire, All rights reserved.